Novo Nordisk Lifts Guidance as Rollout of Wegovy Weight-Loss Pill Continues
By Dominic Chopping
Novo Nordisk raised its guidance for the year after noting an improved outlook for its key obesity and diabetes drugs, particularly in markets outside of the U.S., as it continues the rollout of its new weight-loss pill.
The Danish drugmaker said Wednesday that it expects adjusted sales and operating profit to sit somewhere between a 2% decline and 2% growth at constant exchange rates this year, better than prior guidance for a decline of up to 6% for both metrics.
Analysts had expected Novo to raise its annual guidance on a strong uptake of the Wegovy pill in recently launched markets.
Novo said third-quarter sales of its Wegovy pill reached 5.39 billion Danish kroner, equivalent to $807.2 million, compared with the 4.5 billion kroner expected in an analysts' poll taken from FactSet.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
November 04, 2026 02:20 ET (07:20 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
3 of the Best Dividend Stocks to Own
The 10 Best Companies to Invest in Now
It’s Been a Long Time Since Bonds Looked This Good
United States